Evidence Hub

Severe transient neonatal hyperinsulinism: First Peruvian case series

Manuel André Virú-Loza, Francesca Bermudez-Paredes, Isabel Milagros Arauco-Carhuas

SAGE Open Medical Case Reports, 2025

1 citation

Abstract

Congenital hyperinsulinism is characterized by dysregulated insulin secretion and is the most common and severe cause of persistent hypoglycemia in pediatrics. Brain damage rates can be as high as 50% due to inadequate treatment. Transient congenital hyperinsulinism is more frequent than permanent congenital hyperinsulinism. Acquired hyperinsulinism due to perinatal stress is often transient, too. Diazoxide is the first-line therapy. However, in Peru, reports about pediatric patients with hyperinsulinism treated with diazoxide are scarce. Our article describes the first Peruvian case series of severe transient neonatal hyperinsulinism treated with diazoxide, with good response and manageable adverse effects. Diazoxide should be included in the Single National Pharmaceutical Request Form for Essential Medicines of Peru to expedite the use of a medication as essential as this one.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free